Clinical Trials Logo

Leukemia, Myelogenous, Chronic clinical trials

View clinical trials related to Leukemia, Myelogenous, Chronic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05640804 Completed - Clinical trials for Leukemia, Myelogenous, Chronic

A Bioequivalence Study of Dasatinib Tablet

Start date: September 9, 2018
Phase: Phase 1
Study type: Interventional

This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.

NCT ID: NCT03421626 Completed - Clinical trials for Leukemia, Myelogenous, Chronic

Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)

Start date: November 8, 2017
Phase:
Study type: Observational

The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

NCT ID: NCT02117115 Completed - Multiple Myeloma Clinical Trials

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

GVHD
Start date: June 2014
Phase: Phase 0
Study type: Interventional

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

NCT ID: NCT01720264 Completed - Clinical trials for Acute Myeloid Leukemia

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Start date: November 2, 2012
Phase: Phase 2
Study type: Interventional

The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

NCT ID: NCT00862719 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Sitagliptin Umbilical Cord Blood Transplant Study

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).

NCT ID: NCT00619879 Recruiting - Clinical trials for Leukemia, Lymphoblastic, Acute

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.

NCT ID: NCT00569179 Terminated - Clinical trials for Myelodysplastic Syndromes

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.

NCT ID: NCT00241358 Completed - Multiple Myeloma Clinical Trials

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

Start date: May 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

NCT ID: NCT00129740 Completed - Clinical trials for Leukemia, Myelogenous, Chronic

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Start date: June 27, 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if an experimental agent, AMN107 (nilotinib), can help to control CML in chronic phase. The safety of this experimental agent will also be studied.